IRIS
BANDINI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 446
NA - Nord America 350
AS - Asia 135
Continente sconosciuto - Info sul continente non disponibili 2
Totale 933
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 347
SE - Svezia 238
IT - Italia 99
SG - Singapore 56
RU - Federazione Russa 39
CN - Cina 37
DE - Germania 25
FI - Finlandia 20
TR - Turchia 16
HK - Hong Kong 12
IE - Irlanda 9
IN - India 9
PL - Polonia 4
BE - Belgio 3
IR - Iran 3
CA - Canada 2
EU - Europa 2
GB - Regno Unito 2
GR - Grecia 2
LV - Lettonia 2
MY - Malesia 2
CZ - Repubblica Ceca 1
LT - Lituania 1
MK - Macedonia 1
MX - Messico 1
Totale 933
Salva come PNG Salva come JPEG
Città #
Lawrence 55
Princeton 55
Ashburn 43
Singapore 42
New York 41
Milan 39
Shanghai 31
Boardman 23
Helsinki 18
Moscow 18
Tekirdağ 13
Turin 12
Dublin 9
Brooklyn 8
Hanover 6
Central 5
Hong Kong 5
Pune 5
Genoa 4
Rome 4
Krakow 3
Washington 3
Antwerp 2
Arvada 2
Bari 2
Delhi 2
Detroit 2
Florence 2
Henderson 2
Imola 2
Kiel 2
Lahti 2
Latina 2
Navi Mumbai 2
Palermo 2
Plymouth 2
Polignano a Mare 2
Riga 2
Seattle 2
Seri Kembangan 2
Silver Spring 2
Andover 1
Athens 1
Barrafranca 1
Borås 1
Brussels 1
Cesena 1
Clifton 1
Cosenza 1
Enna 1
Falconara Marittima 1
Gunzenhausen 1
Kahramanmaraş 1
Kaunas 1
Leawood 1
Los Angeles 1
Nuremberg 1
Osimo 1
Perosa Argentina 1
Prague 1
Presezzo 1
Rho 1
Rozzano 1
Sacramento 1
Sesto San Giovanni 1
Tehran 1
Thessaloniki 1
Warsaw 1
Zanjan 1
Zapopan 1
Totale 509
Salva come PNG Salva come JPEG
Nome #
Development of a novel signature integrating clinical, imaging and epigenetic information to tailor pelvic nodal treatment in prostate cancer 146
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 31
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 29
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 26
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 23
A global approach to improving penile cancer care 22
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 22
A risk calculator predicting recurrence in lymph node metastatic penile cancer 21
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 21
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 21
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? 21
Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting 20
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups 19
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 19
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 18
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 17
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 17
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 17
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? 17
Targetable gene fusions and aberrations in genitourinary oncology 16
Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis 15
Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy 15
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 15
Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition 15
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma 14
Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in children with proximal hypospadias 14
Causal contributors to tissue stiffness and clinical relevance in urology 14
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study 13
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer 13
The new era of precision urobiome: RE: “Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study” by Chipollini et al 13
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 13
Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies 13
Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer 12
Revolutionizing care for rare genitourinary tumours 12
Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55–65 12
Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma 11
Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer 11
The effect of race on survival after local therapy in metastatic prostate cancer patients 11
Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis 11
The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer 11
Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma 11
Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636–43 11
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 10
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 10
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages 10
The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis 10
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study 10
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? 10
Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations 10
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab 10
Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines 10
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration 10
Nomograms in urologic oncology, advantages and disadvantages 9
Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma 9
Prevalence and surgical management of pubic hypertrophy in hypospadias patients: Results from a high-volume surgeon 9
Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? 9
The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC) 9
Neoadjuvant chemotherapy for lymph node-positive penile cancer: Current evidence and knowledge 9
Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233–9 9
Topographic modification of the extracellular matrix precedes the onset of bladder cancer 7
Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment 7
Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited 6
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 1
null 1
null 1
null 1
null 1
null 1
Totale 1.012
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.667
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.667
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0 0 0 0 1 0 0 0 2 2 0 0
2020/202132 0 0 0 0 0 25 7 0 0 0 0 0
2021/202296 0 16 3 32 1 0 2 6 2 4 0 30
2022/2023413 131 99 31 11 3 42 11 46 8 3 13 15
2023/2024365 6 25 38 35 33 67 50 40 4 4 16 47
2024/202597 97 0 0 0 0 0 0 0 0 0 0 0
Totale 1.012